Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951651 · ClinicalTrials.gov registry record · Phase 4
Effect of Exenatide on Liver and Heart Fat and Inflammation
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01951651 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT01951651, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.
Interventions
- DRUG Exenatide
- DRUG Glipizide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951651
The ClinicalTrials.gov registry entry for NCT01951651 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide is the first listed.
NCT01951651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951651 about?
NCT01951651 is a clinical study titled "Effect of Exenatide on Liver and Heart Fat and Inflammation". The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.
What is the current status of trial NCT01951651?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2010-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01951651?
The interventions under investigation include: Exenatide (DRUG), Glipizide (DRUG).
Who is sponsoring clinical trial NCT01951651?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.